Precision microbiome technology
Every antibacterial is a sledgehammer. We built the guided arrow.
ArrowBiome® develops precision actives designed to target the key bacteria implicated in acne and body odour, while minimising impact on the skin’s healthy microbiome.
- in-cosmetics Asia Gold Award
- Clinically validated
- Growing patent portfolio
Commercial readiness
From the lab to the shelf: already underway.
ArrowBiome isn’t a concept seeking validation. Our actives are in qualification at the world’s largest beauty companies, moving through formulation and pilot batches, and available to order today through a deepening global distributor network.
Commercially available
Production-ready actives with full technical and formulation support, ready to specify and order now.
Shipping product
Samples, pilot batches and approved-supplier pathways are live with partners across multiple markets.
Expanding distribution
An international distributor network that is deepening and widening across regions, quarter on quarter.
Across the brand spectrum
Trusted by global multinationals and chosen by leading indie brands: the same precision, at every scale.
How partners move with us
A defined path, not a pitch- EvaluationTechnical & specificity review
- Safety clearedToxicology & regulatory passed
- FormulationCo-development in base products
- Pilot batchesScaled validation & consumer panels
- Commercial launchApproved supplier · brand SKUs
Partners are progressing rapidly through these milestones, with multiple programmes already past safety clearance and into formulation and pilot stages.
Working across the full brand spectrum
Engagements span body-odour and acne programmes with major global beauty multinationals, leading skincare brand owners, and top fragrance houses, through to independent and emerging brands.
Why now
The stage is set for a better way.
Four forces are converging at once: a generation of conventional actives is failing the people who use them, while consumers, regulators and the science itself move decisively toward precision. The market isn’t waiting for permission. It’s already migrating.
Select a force to explore the evidence
These forces all point the same way. We’re building the answer. Talk to our team →
Sources: The Silent Migration (2026 Evidence Brief) and The Global State of Skin Microbiome Understanding (2026 Strategic Review); EU SCCS, FDA, Valisure, NACDG, GBD, Yuka, Grand View Research, Nature Biotechnology.
See it in action
Manage the bad. Keep the good.
Watch precision at work: our platform removes only the target bacterium and leaves the beneficial community completely intact, the picture no other microbiome company can show.
ArcherZyme® is a phage-derived enzyme that recognises and selectively acts on bacteria associated with underarm odour, such as S. hominis, while leaving the rest of the skin community undisturbed.
The platform
Two Versatile Technology Platforms. A growing portfolio of applications.
Two proven applications
Clinically validated. Commercially ready.
SmartArrow®: n=34, 28-day dermatologist-supervised clinical study on the SmartArrow particle (rinse-off, no payload). ArcherZyme®: n=27 split-axilla clinical study (van Steensel et al., manuscript accepted).
Platform versatility
Proven in skin. Adaptable far beyond it.
The same precision platform is adaptable to scalp, oral, feminine, gut and more. Our current commercial focus is acne and body odour; adjacencies are demand-led.
See platform versatilityAcne
✓ Proven
Body Odour
✓ Proven
Scalp & Hair
Adaptable
Oral Care
Adaptable
Feminine
Adaptable
Gut & AMR
Adaptable
Why it’s different
Clinically validated
Gold-standard human studies for both lead actives.
Selective by design
Removes the target bacterium; preserves the rest.
Ultra-low dose
Effective from concentrations as low as 0.01%.
Patent-protected
MIT-licensed and wholly-owned IP across applications.
Wherever you’re coming from
